ElevateBio names Carpenter as Chief Scientific Officer of Regenerative Medicine
9 December 2019 - - US-based cell and gene therapy holding company ElevateBio has appointed Melissa K. Carpenter, Ph.D. to the newly created position of chief scientific officer of regenerative medicine, the company said.

Carpenter will be responsible for expanding ElevateBio's portfolio of companies by identifying and forming partnerships with leading academia and industry partners developing stem cell-based regenerative therapies.

She has been involved with human pluripotent stem cell research since the field was established and brings invaluable experience to the team.

Carpenter brings more than 25 years of academic and industry experience in the development of cell therapies using human adult and pluripotent stem cells.

Prior to joining ElevateBio, Dr. Carpenter managed her own consulting firm, helping numerous academic teams and companies to navigate and find success in the field.

Before this, Carpenter was vice president, Research and Development at NovoCell Inc. (now Viacyte, Inc), where she was responsible for translating stem cell research programs to preclinical development, as well as developing the regulatory strategy for the delivery of an encapsulated human embryonic stem cell-derived product into diabetes patients.

Carpenter also held the position of Principal Investigator and Scientist at the Robarts Research Institute and Associate Professor, Faculty of Medicine at the University of Western Ontario, where her lab focused on the epigenetic status of undifferentiated human embryonic stem cells and the signaling mechanisms involved in self-renewal.

She was director of Stem Cell Biology at Geron, Corp. (assets acquired by Asterias) where she was responsible for managing discovery research and preclinical programs aimed at developing therapies for Parkinson's disease, spinal cord injury, cardiac disease, liver disease and diabetes.

Prior to that position, she worked at CytoTherapeutics, Inc. (now StemCells, Inc), deriving human neural stem cells and successfully developing the media formulation used for scale-up of these cells.

Carpenter has been named inventor on 34 issued US patents and has over 50 peer reviewed publications in the stem cell field.

She received her Ph.D. from the Laboratory of Cellular and Molecular Neurobiology at University of California, Irvine and received her B.Sc. in Psychology from University of Oregon.

ElevateBio, LLC, is a Cambridge-based cell and gene therapy holding company, established to create and operate a broad portfolio of cell and gene therapy companies with leading academic researchers, medical centers and entrepreneurs.

ElevateBio builds single- and multi-product companies by providing scientific founders with fully integrated bench-to-bedside capabilities including world-class scientists, manufacturing facilities, drug developers and commercial expertise.

ElevateBio BaseCamp, a company-owned Cell and Gene Therapy Center of Innovation, will serve as the R and D, process development and manufacturing hub across the entire ElevateBio portfolio while also supporting selected strategic partners.

ElevateBio's lead investors are MPM Capital and F2 Ventures. Investors also include EcoR1 Capital, Redmile Group, and Samsara BioCapital.